Trial Title:
A Study of Telemonitoring in Cancer Patients
NCT ID:
NCT06381024
Condition:
Cancer
Conditions: Keywords:
remote patient monitoring
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Intervention model description:
Patients initiating either oral or intravenous chemotherapy for cancer will be randomly
allocated in a 1:1 ratio to either:
- In-person care alone (Standard of care group).
- In-person care with telemonitoring (Standard of care with Cureety group).
The randomization will be stratified by:
• Oral versus intravenous cancer treatment. The number of patients initiating oral
treatment at randomization will be restricted to 20 patients.
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Device
Intervention name:
remote patient monitoring
Description:
Cureety is a digital telemonitoring platform, specifically designed to monitor signs and
symptoms of disease progression and AEs in cancer patients. The digital tool is adaptable
to specific treatments and disease settings. The platform collects various data including
treatment delays, dose reductions, quality of life and safety data. In terms of safety,
once configured for the treatment and disease setting, the patient responds to an
electronic PRO (ePRO) questionnaire based on the NCI-CTCAE version (v)5.0.10 Depending on
the responses, an algorithm classifies patients as either "correct", "compromised",
"state to be monitored", or "critical state". Depending on the classification, patients
are notified of the actions to be taken.
Arm group label:
Standard of care with Cureety group
Other name:
Cureety
Summary:
The goal of this prospective, randomized, unblinded, single-centre, interventional study
is to assess the effectiveness of standard of care with Cureety, compared to standard of
care alone, to reduce the number of all telephone calls during the first 4 months of oral
or intravenous cancer treatment for patients older than 18 years of age, initiating oral
or intravenous cancer treatment at the Centre Hospitalier de Bligny.
Patients initiating either oral or intravenous chemotherapy for cancer will be randomly
allocated in a 1:1 ratio to either:
- In-person care alone (Standard of care group).
- In-person care with Cureety telemonitoring (Standard of care with Cureety group).
Participants will:
- be monitored with digital application Cureety (Standard of care with Cureety group)
- fill out quality of life questionnaire (baseline, 2 months, 4 months)
- fill out satisfaction questionnaire (2 months, 4 months)
- have the ongoing and incoming phone calls logged (duration and type)
Detailed description:
Rationale:
Telemonitoring of cancer patients provides patients with cancer-related information, as
well as allowing appointment management, early detection of side-effects/adverse events
(AEs), and the collection of safety and quality of life data from the patients'
perspectives.1 Several studies have assessed the benefit of telemonitoring from the
patients' perspective.1-5 However, few studies have investigated the benefit of
telemonitoring for healthcare professionals.4,6,7 The Symptom Tracking and Reporting
(STAR) randomized trial, performed at the Memorial Sloan Kettering Institute, randomly
allocated patients to either usual care or the patient-reported outcome (PRO) group.8,9
Patients in the PRO group completed a web-based questionnaire concerning 12 common AEs
(based on the National Cancer Institute Common Terminology Criteria for AEs [NCI-CTCAE
version (v) 5.0]10) at or between visits. In the PRO group, 63% of patients reported
severe AEs during the study. Patients, in the PRO group, reported improved quality of
life, fewer admissions to emergency rooms or hospitalization, extended duration of
chemotherapy, and extended overall survival (OS). This increased OS is potentially due to
the early response by healthcare professionals to severe AEs identified by the web-based
questionnaire. For healthcare professionals, the study reported fewer unscheduled visits
for patients allocated to the PRO group.
Interestingly, in the STAR trial, 77% of the nurse interventions (either by email or
telephone) were in response to alerts (either counseling or symptom management), 12% were
for initiating or changing of supportive treatment, 8% were for referrals to the
emergency room or hospital, 2% were for chemotherapy dose modifications, and 2% were for
ordering imagery or biological test.11 In France, the Foch hospital initiated the Star
program for patients undergoing chemotherapy.12 The program collects patient data within
at most 3 days prior to each chemotherapy session and transfer these to healthcare
professionals to prepare the chemotherapy. The patient has the choice of completing a
questionnaire via the internet or providing the information by telephone with the aid of
a nurse. The data includes health status, presence of AEs, and blood test results. These
data allow healthcare professionals to adapt or delay the chemotherapy, change
treatments, and provide the patient with personalized advice according to the patient's
health status. The program has improved the performance of departments involved by
increasing the number of patients treated per day, decreasing the waiting times for
patients, and by reducing the wastage of healthcare products.
Consequently, numerous French healthcare centers want to implement programs like the Star
program. However, a substantial portion of the data collection occurs via the telephone,
particularly outgoing calls (from the hospital staff to patients). This increase in
telephone communication means more work for healthcare professions. A digital
telemonitoring platform, like Cureety that can collect this data before chemotherapy, is
expected to decrease outgoing calls by between 30% to 50% and facilitate the implementing
of these programs.
Furthermore, healthcare centers in France are continually facing budget restrictions. At
the same time, treating cancer patients is associated with an increase in incoming calls
from patients during cancer treatment, particularly for minor AEs. The treating of these
incoming calls is often repetitive and time consuming for hospital staff. The collection
of data concerning AEs, of varying severity, can be integrated in a digital platform.
Patients with minor AEs can be provided with the actions to be followed via the platform.
This will allow staff to concentrate on patients with severe AEs needing urgent
attention.
Cureety is a digital telemonitoring platform, specifically designed to monitor signs and
symptoms of disease progression and AEs in cancer patients. The digital tool is adaptable
to specific treatments and disease settings. The platform collects various data including
treatment delays, dose reductions, quality of life and safety data. In terms of safety,
once configured for the treatment and disease setting, the patient responds to an
electronic PRO (ePRO) questionnaire based on the NCI-CTCAE version (v)5.0.10 Depending on
the responses, an algorithm classifies patients as either "correct", "compromised",
"state to be monitored", or "critical state". Depending on the classification, patients
are notified of the actions to be taken.
This study will assess the benefit of adding Cureety telemonitoring to standard of care,
compared to standard of care alone, for monitoring cancer patients undergoing oral or
intravenous cancer treatments.
Methodology:
The MINERVA study was designed as a prospective, randomized, unblinded, single-centre,
interventional study with minimal risks and constraints for patients.
Patients initiating either oral or intravenous chemotherapy for cancer will be randomly
allocated in a 1:1 ratio to either:
- In-person care alone (Standard of care group).
- In-person care with telemonitoring (Standard of care with Cureety group).
The randomization will be stratified by:
• Oral versus intravenous cancer treatment. The number of patients initiating oral
treatment at randomization will be restricted to 20 patients.
Data concerning the telephone calls between study patients and the staff at the CH Bligny
will be collected. The incoming and outgoing calls from the CH Bligny will be classified
in the following categories:
- Cancer treatments information (including the use of associated prophylactic
treatments, e.g., granulocyte colony-stimulating factor [G-CSF], antihistamines
etc.)
- Appointments, in the following subcategories:
- Administration of cancer therapy (including oral and intravenous treatments,
etc.).
- Consultations for a reason other than administering therapy.
- Blood tests and other examinations.
- Prescriptions.
- Biological examinations (in preparation for cancer treatment).
- Psychological support.
- Patient education and supportive care.
- Cancer treatment-related AEs.
- Non-cancer treatment-related AEs, excluding COVID-related.
- COVID-related.
- Related to Cureety.
- Other calls. The planned enrolment period is 5 months. The planned follow-up period
for each patient is 4 months.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Patients that have provide written informed consent for study participation.
2. Patients aged 18 years or older.
3. Patients initiating oral or intravenous treatment (chemotherapy, immunotherapy,
targeted therapies etc.) for localized or metastatic or recurrent cancer treated at
the CH Bligny.
4. Patients with the capacity, personally (e.g., language and capacity to use the
application), and in terms of infrastructure (internet access, possessing a smart
phone etc.) to perform telemonitoring with Cureety.
5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
Exclusion Criteria:
- Patients treated for cancer at the CH Bligny in the last 5 years
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Centre Hospitalier de Bligny
Address:
City:
Briis-sous-Forges
Zip:
91640
Country:
France
Status:
Recruiting
Contact:
Last name:
Ingrid Alexandre, MD
Phone:
+33169263138
Email:
i.alexandre@chbligny.fr
Investigator:
Last name:
Ingrid Alexandre, MD
Email:
Principal Investigator
Start date:
April 4, 2023
Completion date:
December 30, 2024
Lead sponsor:
Agency:
Centre Hospitalier de Bligny
Agency class:
Other
Collaborator:
Agency:
Exystat
Agency class:
Other
Collaborator:
Agency:
Cureety
Agency class:
Industry
Collaborator:
Agency:
Pharmaspecific
Agency class:
Other
Collaborator:
Agency:
ProPens
Agency class:
Other
Source:
Centre Hospitalier de Bligny
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06381024
